Estimate your vaccine queue position in South Africa. Model rollout timelines with adjustable population, supply, priority groups, and uptake.
South Africa, with approximately 62 million people, uses a mixed public-private health system across nine provinces. This Vaccine Queue Estimator models rollout logistics using South Africa-style supply, uptake, and priority-group assumptions.
The National Department of Health coordinates vaccination strategy, while provinces and local providers handle delivery through public hospitals, clinics, community health centres, pharmacies, and campaign sites. Registration and appointment tracking commonly run through EVDS or the current national platform.
The country’s rollout pattern can vary sharply by province, urban density, and campaign type, so the calculator is useful for comparing queue timing under different supply profiles. It is especially helpful when you want to see how a backlog in higher-priority groups changes the week you reach the front of the line.
Use this to estimate how supply constraints and provincial rollout differences affect when a person or community group is likely to be vaccinated. It is also useful for district managers comparing coverage pace across public and private delivery channels.
Doses Before You = People in Higher Priority Groups × Doses/Person Weeks to Your Turn = Cumulative weeks until growing supply covers prior groups Full Coverage = Weeks until all target doses administered
Result: ~17 weeks until Group 5 begins
Groups 1-4 cover 31% of 40.3M target = 12.5M people = 25M doses. At 1.14M usable/week growing 3%, coverage takes ~17 weeks.
South Africa operates a dual healthcare system: public sector (serving ~84% of the population) and private sector (~16%). The National Health Insurance (NHI) initiative aims to bridge this gap. For vaccination, both sectors are leveraged, with the NDoH coordinating supply and provinces managing delivery.
South Africa's nine provinces have widely varying healthcare capacity. Gauteng and Western Cape have the most developed infrastructure, while Eastern Cape and Limpopo face greater challenges. Provincial variation in vaccination speed reflects these infrastructure differences and rural-urban divides.
South Africa is positioning itself as the continent's vaccine manufacturing centre. The WHO mRNA technology transfer hub in Cape Town, Aspen Pharmacare's fill-and-finish facility, and Biovac's production capabilities collectively aim to reduce Africa's dependence on imported vaccines and build long-term health security.
Last updated:
This worksheet uses population, weekly supply, uptake, wastage, and priority-tier assumptions to estimate when the selected group might be reached. It is a planning model, not a booking forecast, and local eligibility or shipment timing can shift the result.
The NDoH coordinates nationally with provinces managing delivery. Vaccines are administered at public hospitals, community health centres, pharmacies, and pop-up vaccination sites. The EVDS manages registration and appointments.
Vaccine hesitancy, misinformation, access barriers in rural areas, and trust issues influenced by historical healthcare inequities all affect uptake. Targeted outreach through community health workers and trusted leaders helps improve rates.
Aspen Pharmacare in Gqeberha has supported fill-and-finish capacity and supply resilience for South Africa and the wider region, which can affect how much local stock is available in a given campaign.
Mobile units, outreach teams, and temporary sites at community centres, churches, and transport hubs are often used to reduce access barriers in underserved areas.
Yes. South Africa has invested in mRNA vaccine technology transfer through the WHO hub in Cape Town, along with existing manufacturing by Aspen and Biovac, positioning the country as Africa's vaccine production leader.
Yes. South Africa's vaccination programmes include all residents regardless of nationality or documentation status, recognizing that public health requires comprehensive coverage.